Market Cap
$1.1B
TDOC
Teladoc Health, Inc.
$5.52 ▼ -2.65%
Prev close $5.67Market cap$1.1B
ConsensusSell
12-mo target$7.68 (+39.1%)
▼ Bearish
Analyst conviction 4/10
Insider Selling Cluster (6 insiders)High Impact Filing (8/10)22 New Institutional Positions28 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on TDOC right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Hold (35%)
Inst. Holders
50 funds
Inst. Value
$1.1B
Inst. Activity
22 buys / 28 sells
Insider Activity
$0.00 buy / $959.0K sell
Insider Net $
-$959.0K
Social Sentiment
50° Neutral
SEC Reports
16
Press Releases
1
Price chart 30d -14.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 short_volume
Sep 11, 2026 SEC Short Volume: TDOC — 58.6% short (0.8M / 1.4M)
Short: 847,132 | Exempt: 1,462 | TRF Vol: 1,444,614 | Short Ratio: 58.6% | Off-exchange volume (dark
Charles Divita, a Director and Officer of Teladoc Health, filed a Form 144 notice of intent to sell 17,805 shares of com
144 — Impact 2/10
Sep 11, 2026 Insider
DIVITA CHARLES III sold 17,805 shares
CHIEF EXECUTIVE OFFICER @ $6.10 ($108.7K)
Sep 10, 2026 Insider
DIVITA CHARLES III acquired via exercise 3,642 shares
CHIEF EXECUTIVE OFFICER
Sep 10, 2026 Insider
Sep 4, 2026 SEC DIVITA CHARLES III acquired via exercise 39,160 shares
CHIEF EXECUTIVE OFFICER
CEO Charles Divita and CLO Adam Vandervoort sold a combined $163K in open-market shares at ~$6.30 on September 2, 2026.
CLUSTER — Impact 2/10
Director Charles Divita III filed a Form 144 to sell 18,327 shares of Teladoc Health, Inc. at an estimated value of $115
144 — Impact 2/10
Jun 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC — ADD
4,894,504 shares ($41.5M)
Analyst ratings buy % +20.7%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
35% rate it Buy or better · 31 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 3, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Jul 30, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 30, 2026 | Evercore ISI Group | MAINTAIN | In-Line | 59% |
| Jul 21, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 7, 2026 | B of A Securities | MAINTAIN | Buy | 54% |
| May 5, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
| Apr 8, 2026 | Evercore ISI Group | MAINTAIN | In-Line | 59% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 20 | 0 | 0 | 35% | |
| Aug 1, 2026 | 4 | 7 | 20 | 0 | 0 | 35% | |
| Jul 1, 2026 | 4 | 8 | 20 | 0 | 0 | 38% | |
| Jun 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| May 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| Apr 1, 2026 | 4 | 8 | 21 | 0 | 0 | 36% | |
| Mar 1, 2026 | 4 | 7 | 23 | 0 | 0 | 32% | |
| Feb 1, 2026 | 3 | 7 | 24 | 0 | 0 | 29% |
Price targets
Where 17 covering analysts think TDOC trades over the next 12 months.
$7.68 +39.1% upside Strong Buy
Current$5.52 Low$5.50 Median$7.50 High$10.50 17 analysts
$5.50$10.50
Analyst rating Hold· 2.5/5 as of Oct 3, 2026
Social media sentiment mood -20.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 0 bullish, 4 bearish, 1 mixed, 11 neutral · avg impact 3.8/10.Plus 1 press releases.
NEUTRAL1442/10
Charles Divita, a Director and Officer of Teladoc Health, filed a Form 144 notice of intent to sell
Sep 11, 2026
NEUTRALCLUSTER2/10
CEO Charles Divita and CLO Adam Vandervoort sold a combined $163K in open-market shares at ~$6.30 on
Sep 4, 2026
NEUTRAL1442/10
Director Charles Divita III filed a Form 144 to sell 18,327 shares of Teladoc Health, Inc. at an est
Sep 2, 2026
BEARISHPRESS-RELEASE8/10
Teladoc Health (TDOC) shares fell over 28% after reporting Q2 2026 revenue of $606.9M, below the con
Aug 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
short_volume
Short Volume: TDOC — 58.6% short (0.8M / 1.4M)
Short: 847,132 | Exempt: 1,462 | TRF Vol: 1,444,614 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Sep 30, 2026
short_volume
Short Volume: TDOC — 59.1% short (0.8M / 1.4M)
Short: 834,553 | Exempt: 665 | TRF Vol: 1,411,903 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
other
Teladoc Health Announces Chief Legal Officer Transition
Jonathan Dorfman to be promoted to Chief Legal Officer and Secretary effective November 2, 2026 Jonathan Dorfman to be promoted to Chief Legal Officer
Sep 25, 2026
short_volume
Short Volume: TDOC — 61.1% short (0.7M / 1.2M)
Short: 741,924 | Exempt: 1,463 | TRF Vol: 1,214,590 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: TDOC — 65.5% short (0.7M / 1.0M)
Short: 684,065 | Exempt: 986 | TRF Vol: 1,043,645 | Short Ratio: 65.5% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.20 | $-0.23–$-0.18 | -9.2% | +0.0% | 0↑ 2↓ | $0.6B | 2 |
| Next Q | $-0.12 | $-0.19–$-0.04 | -11.2% | +0.0% | 1↑ 1↓ | $0.6B | 2 |
| Current FY | $-0.78 | $-0.99–$-0.65 | -19.4% | +0.0% | 1↑ 2↓ | $2.4B | 3 |
| Next FY | $-0.79 | $-1.02–$-0.55 | -0.2% | +0.0% | 1↑ 1↓ | $2.4B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.205 | — |
| 7d ago | $-0.205 | — |
| 30d ago | $-0.205 | — |
| 60d ago | $-0.150 | -0.055 |
| 90d ago | $-0.173 | -0.032 |
Institutional ownership
Which big funds own TDOC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.1B total value (128,082,729 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, Point72. Net selling activity: 28 institutions trimmed/exited vs 22 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 16,223,134 | $137.6M | 12.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 12,685,592 | $107.6M | 9.9% | — |
| Point72 Asset Management, L.P. | 8,239,927 | $69.9M | 6.4% | — |
| RENAISSANCE TECHNOLOGIES LLC | 8,072,842 | $68.5M | 6.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,955,032 | $67.5M | 6.2% | — |
| DIMENSIONAL FUND ADVISORS LP | 7,371,699 | $62.5M | 5.8% | — |
| STATE STREET CORP | 4,962,382 | $42.1M | 3.9% | — |
| AMERICAN CENTURY COMPANIES INC | 4,894,504 | $41.5M | 3.8% | ADD +41.6% |
| Allianz Asset Management GmbH | 4,666,596 | $39.6M | 3.6% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,653,834 | $39.5M | 3.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | 3,456,384 | 4,894,504 | +41.6% | $41.5M |
| GOLDMAN SACHS GROUP INC | ADD | 2,706,335 | 3,822,284 | +41.2% | $32.4M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | NEW | — | 2,040,051 | — | $17.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | 885,526 | 1,324,231 | +49.5% | $11.2M |
| Allspring Global Investments Holdings, LLC | DOUBLED | 276,669 | 991,742 | +258.5% | $9.0M |
| Freestone Grove Partners LP | TRIM | 1,509,954 | 865,349 | -42.7% | $7.3M |
| Man Group plc | TRIM | 3,021,550 | 811,385 | -73.1% | $6.9M |
| CITADEL ADVISORS LLC | ADD | 587,683 | 770,294 | +31.1% | $6.5M |
| FMR LLC | DOUBLED | 30,123 | 760,504 | +2424.7% | $6.4M |
| TCW GROUP INC | ADD | 544,697 | 736,797 | +35.3% | $6.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 50 transactions. Net -$959.0K — $0.00 bought, $959.0K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | SELL | 17,805 | $6.10 | $108.7K |
| Sep 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | EXERCISE | 3,642 | — | — |
| Sep 10, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | EXERCISE | 39,160 | — | — |
| Sep 3, 2026 | Rodrigues Fernando M. | President of BetterHelp | SELL | 9,812 | $6.51 | $63.9K |
| Sep 2, 2026 | Bliss Kelly | President, U.S. Group Health | SELL | 7,357 | $6.30 | $46.4K |
| Sep 2, 2026 | Nueno Carlos | President, International | SELL | 6,200 | $6.30 | $39.1K |
| Sep 2, 2026 | Rodrigues Fernando M. | President of BetterHelp | SELL | 5,439 | $6.30 | $34.3K |
| Sep 2, 2026 | Catapano Joseph Ronald | Chief Accounting Officer | SELL | 274 | $6.30 | $1.7K |
| Sep 2, 2026 | DIVITA CHARLES III | CHIEF EXECUTIVE OFFICER | SELL | 18,327 | $6.30 | $115.5K |
| Sep 2, 2026 | Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | SELL | 7,573 | $6.30 | $47.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TDOC.
Shares short
27,626,898
Settlement Sep 15, 2026
Change vs prior
+9.0%
Semi-monthly cycle
Days to cover
8.5
At avg daily volume
Of shares outstanding
≈15.2%
Estimate — not % of float
All TDOC filing & press-release reports (17)
- 144 reportSep 11, 2026
- CLUSTER reportSep 4, 2026
- 144 reportSep 2, 2026
- PRESS-RELEASE reportAug 7, 2026
- PRESS-RELEASE reportJul 31, 2026
- 144 reportJun 29, 2026
- 144 reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- 144 reportJun 2, 2026
- 144 reportJun 2, 2026
- PRESS-RELEASE reportApr 15, 2026
- DEFA14A reportApr 7, 2026
- 3 reportApr 1, 2026
- PRESS-RELEASE reportMar 30, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 3, 2026
- 8-K reportFeb 26, 2026